explore -WSS

explore

author：focus 2025-10-02 03:55:32 Page View：54

Rachel Haurwitz of Caribou Biosciences — Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In his State of the Union, Biden takes clear aim at 'Big Pharma'
Next article： Heart attack and stroke risk calculators need revising

leisure time

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Alexander Hamilton and the argument for universal insurance

AdobeEveryoneknowsthattheUnitedStatesistheonlyhigh-incomecountrywithoutuniversalhealthinsurance.Acco

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Headspace, Meta partner to launch VR meditation app for Quest

HeadspaceXR,developedwithfundingfromMeta,guidesusersthroughmeditationandotheractivities,suchasaTaiCh